Clinical Trial Update: Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease [Phase 1]

View source ↗

Summary

Phase 1 trial of irradiated donor lymphocytes with rituximab for relapsed or refractory lymphoproliferative disease; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• Irradiated donor lymphocytes
• Rituximab (rituximab)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Leukemia, Lymphoma | Phase 1 | Status: TERMINATED